Netupitant-Palonosetron FDC Market Report 2026

Netupitant-Palonosetron FDC Market Overview

• Netupitant-Palonosetron FDC market size has reached to $384.5 billion in 2025 • Expected to grow to $608.99 billion in 2030 at a compound annual growth rate (CAGR) of 9.6% • Growth Driver: Increase In Cancer Incidence Fueling The Growth Of The Market Due To Rising Chemotherapy Demand • Market Trend: New Ready-To-Use Intravenous Injection Enhances Convenience And Safety In Chemotherapy Care • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Netupitant-Palonosetron FDC Market?

The netupitant-palonosetron fixed-dose combination (FDC) is a pharmaceutical formulation that combines two active ingredients, netupitant, a neurokinin-1 (NK1) receptor antagonist, and palonosetron, a serotonin (5-HT3) receptor antagonist into a single dose. This combination is primarily used to prevent acute and delayed nausea and vomiting associated with chemotherapy. Netupitant works by blocking the action of substance P at NK1 receptors in the brain, while palonosetron inhibits serotonin activity at 5-HT3 receptors, which are key pathways involved in chemotherapy-induced nausea and vomiting (CINV). The main product types of netupitant-palonosetron fixed dose combination (FDC) are netupitant, palonosetron, and fixed-dose combination (FDC). Netupitant is a medication used to prevent nausea and vomiting caused by chemotherapy by blocking substance P/neurokinin 1 (NK1) receptors. It is administered through oral, intravenous (IV), and sublingual routes and is applied in managing chemotherapy-induced nausea and vomiting (CINV), postoperative nausea and vomiting (PONV), and general nausea. It is distributed through various channels such as hospitals, retail pharmacies, online pharmacies, and specialty clinics.

What Is The Netupitant-Palonosetron FDC Market Growth Forecast?

The netupitant-palonosetron fdc market size is expected to see strong growth in the next few years. It will grow to $608.99 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to development of novel fdc formulations, expansion of oral and sublingual drug delivery, rising investment in oncology treatments, adoption of personalized antiemetic regimens, increasing penetration through online and specialty pharmacies. Major trends in the forecast period include rising adoption of fixed-dose combination (fdc) therapies, increasing use of oral and sublingual anti-nausea treatments, expansion of chemotherapy and oncology care facilities, growing awareness about postoperative nausea and vomiting management, enhanced focus on patient-centric drug delivery systems.

Global Netupitant-Palonosetron FDC Market Segmentation

1) By Product Type: Netupitant, Palonosetron, Fixed Dose Combination (FDC) 2) By Route Of Administration: Oral Administration, Intravenous (IV) Administration 3) By Application: Chemotherapy Induced Nausea And Vomiting (CINV), Postoperative Nausea And Vomiting (PONV) 4) By Distribution Channel: Hospitals, Retail Pharmacies, Online Pharmacies, Specialty Clinics Subsegments: 1) By Netupitant: Oral Netupitant, Injectable Netupitant 2) By Palonosetron: Oral Palonosetron, Injectable Palonosetron 3) By Fixed Dose Combination: Oral Fixed Dose Combination, Intravenous Fixed Dose Combination

What Is The Driver Of The Netupitant-Palonosetron FDC Market?

The increasing prevalence of cancer is expected to propel the growth of the netupitant-palonosetron fixed-dose combination (FDC) market going forward. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The increasing prevalence of cancer is due to lifestyle choices such as poor diet, smoking, physical inactivity, and excessive alcohol consumption. Netupitant-palonosetron fixed-dose combination (FDC) enhances cancer treatment by combining two effective antiemetic agents, preventing both acute and delayed chemotherapy-induced nausea and vomiting. They improve patient comfort and adherence to treatment, supporting better overall care outcomes. For instance, in February 2025, according to Cancer Australia, an Australia-based government agency, there were 4,641 new pancreatic cancer cases in 2024, with 2,414 in males and 2,227 in females, marking an increase from 3,968 cases in 2023. Therefore, the increasing prevalence of cancer is driving the growth of the netupitant-palonosetron fixed-dose combination (FDC) market.

Key Players In The Global Netupitant-Palonosetron FDC Market

Major companies operating in the netupitant-palonosetron fdc market are Taiho Pharmaceutical Co. Ltd., Aurobindo Pharma Limited, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd, Dr. Reddy’s Laboratories Ltd., Zhejiang Tiantai Pharmaceutical Co. Ltd., Hikma Pharmaceuticals PLC, Glenmark Pharmaceuticals Limited, Helsinn Group, Heron Therapeutics Inc., Metrochem API Private Limited, Mundipharma Pty Ltd, Guangzhou Tosun Pharmaceutical Co. Ltd., Tesaro Inc., Accord Healthcare Ltd., Century Pharmaceuticals Ltd., Specialised Therapeutics Australia Pty Ltd., Aark Pharmaceuticals Ltd., Chemicea Pharmaceuticals Pvt. Ltd., Teva Pharmaceutical Industries Ltd.

Global Netupitant-Palonosetron FDC Market Trends and Insights

Major companies operating in the netupitant-palonosetron fixed dose combination (FDC) market are focusing on developing advanced formulation products, such as ready-to-use intravenous formulations, to enhance patient convenience and treatment efficacy. Ready-to-use intravenous formulations are pre-prepared, sterile drug solutions that eliminate the need for dilution or mixing, helping netupitant-palonosetron fixed dose combination (FDC) by simplifying administration and reducing preparation errors. For instance, in June 2024, Helsinn Group, a Switzerland-based pharmaceutical company, launched AKYNZEO (fosnetupitant/palonosetron) injection, a ready-to-use vial made available in the United States. This new formulation is designed to simplify preparation and administration for healthcare providers, enhancing convenience in clinical settings. The injection requires no reconstitution or dilution and can be infused directly from the vial using an integrated hanging strap

What Are Latest Mergers And Acquisitions In The Netupitant-Palonosetron FDC Market?

In January 2025, Helsinn Healthcare SA (Helsinn Group), a Switzerland-based pharmaceutical company, partnered with ESTEVE, S.A. to renew their distribution and licensing agreement for AKYNZEO (netupitant-palonosetron) and ALOXI (palonosetron) in Germany. With this partnership, Helsinn and ESTEVE aim to ensure continued patient access to essential supportive care therapies for chemotherapy-induced nausea and vomiting (CINV), strengthening their long-standing collaboration in oncology supportive care. ESTEVE S.A. is a Spain-based specialty pharma company focused on highly specialized treatments.

Regional Insights

North America was the largest region in the netupitant-palonosetron fixed dose combination (FDC) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Netupitant-Palonosetron FDC Market?

The netupitant-palonosetron fixed dose combination (FDC) market consists of sales of oral capsules, injectable formulations, premixed infusion bags, combination therapy kits, and generic versions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Netupitant-Palonosetron FDC Market Report 2026?

The netupitant-palonosetron fdc market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the netupitant-palonosetron fdc industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.